FSTL3 and colorectal cancer: The work of Chao Yang et al. showed that FSTL3 can serve as a bioindicator of ECM remodeling in colorectal cancer and correlates with chemoresistance, and in particular they reported an extremely strong association between FSTL3 and CAFs80.